Information  X 
Enter a valid email address

Ilika plc (IKA)

  Print      Mail a friend       Annual reports

Tuesday 08 October, 2019

Ilika plc

Battery Patent Update

RNS Number : 0401P
Ilika plc
08 October 2019
 

Ilika plc

("Ilika" or the "Company")

 

Battery Patent Update

 

Ilika (AIM: IKA), a pioneer in solid-state battery technology, announces that it has been granted eight of its Stereax® solid-state battery patent filings in five patent jurisdictions.

 

Over the past two years, Ilika has seen substantial progress in the prosecution of this aspect of its patent portfolio at the Patent Offices of China, Korea, Japan, USA and Europe.  As a result, three of its patent families are significantly stronger, with eight related filings going to grant and notices of allowance being issued for a further four.

 

These patent filings protect the methods used to make Ilika's thin-film solid-state Stereax® cells. The Stereax® roadmap commenced with miniature batteries designed to meet the demands of powering wireless devices and has been extended to include large format cells for automotive. 

 

Ilika's CEO Graeme Purdy said: "Protecting Ilika's know-how relating to solid-state batteries is key to our ability to grow our business. We take this very seriously and employ a Vice President of Intellectual Property, who is seconded to the Company from an international firm of patent lawyers to manage this process for us. This strategy is validated by the continued stream of granted patents reinforcing our position."

 

 

 

For more information contact:

 

Ilika plc

 

Graeme Purdy, Chief Executive

Tel: 023 8011 1400

Steve Boydell, Finance Director

 

 

 

Liberum Capital Limited

Tel: 020 3100 2000

Andrew Godber, Cameron Duncan, William Hall

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 / [email protected]

Lianne Cawthorne

Mob: 07584 391 303

Nick Rome

Mob: 07748 325 236

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
UPDUBRVRKOARRAA

a d v e r t i s e m e n t